Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Background Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therap...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shuai Tan, Yuxin Li, Yaofang Cao, Wanling Sun, Wuhan Hui
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2026-12-01
Colecção:	Annals of Medicine
Assuntos:	Ruxolitinib myelofibrosis (MF) combination therapy systematic review meta-analysis
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/07853890.2026.2634532
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!